Critical Care

  • Post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’
    Susan Vehar, MD, Marina Boushra, MD, Prince Ntiamoah, MD and Michelle Biehl, MD, MS
    Cleveland Clinic Journal of Medicine May 2021, 88 (5) 267-272; DOI: https://doi.org/10.3949/ccjm.88a.21010

    An estimated 10% of COVID-19 survivors continue to experience symptoms weeks to months after symptoms appear.

  • Is regular oxygen supplementation safe for obese postoperative patients?
    Roop Kaw, MD and Anthony G. Doufas, MD, PhD
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 723-727; DOI: https://doi.org/10.3949/ccjm.87a.19051

    Caution for some, but no evidence to support withholding it altogether.

  • Neurologic complications of COVID-19
    Catherine E. Hassett, DO, Aron Gedansky, MD, Ibrahim Migdady, MD, Adarsh Bhimraj, MD, Ken Uchino, MD and Sung-Min Cho, DO
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 729-734; DOI: https://doi.org/10.3949/ccjm.87a.ccc058

    Human coronaviruses, including SARS-CoV-2, can be neurotropic.

  • Recognition and management of respiratory co-infection and secondary bacterial pneumonia in patients with COVID-19
    Chao-Ping Wu, MD, Fatima Adhi, MD and Kristin Highland, MD
    Cleveland Clinic Journal of Medicine November 2020, 87 (11) 659-663; DOI: https://doi.org/10.3949/ccjm.87a.ccc015

    Consider the presentation and trajectory of illness.

  • Convalescent plasma for COVID-19: Promising, not proven
    Simon R. Mucha, MD and NurJehan Quraishy, MD
    Cleveland Clinic Journal of Medicine November 2020, 87 (11) 664-670; DOI: https://doi.org/10.3949/ccjm.87a.ccc056

    The evidence is suggestive but weak. Trials are ongoing.

  • SARS-CoV-2 and myocardial injury: Few answers, many questions
    SARS-CoV-2 and myocardial injury: Few answers, many questions
    Paul C. Cremer, MD
    Cleveland Clinic Journal of Medicine September 2020, 87 (9) 521-525; DOI: https://doi.org/10.3949/ccjm.87a.ccc001

    What is the mechanism? Is this a distinct population? What are the treatment options?

  • Management of patients with COVID-19 in the MICU
    Chao Ping Wu, MD, Mani Latifi, MD and Eduardo Mireles-Cabodevila, MD
    Cleveland Clinic Journal of Medicine September 2020, 87 (9) 526-531; DOI: https://doi.org/10.3949/ccjm.87a.ccc017

    The main goals are to ensure caregiver safety and provide the highest quality care.

  • Coagulopathy in COVID-19: Manifestations and management
    Simon R. Mucha, MD, Siddharth Dugar, MD, Keith McCrae, MD, Douglas Joseph, DO, John Bartholomew, MD, Gretchen L. Sacha, PharmD, RPh, BCCCP and Michael Militello, PharmD, RPh, BCPS
    Cleveland Clinic Journal of Medicine August 2020, 87 (8) 461-468; DOI: https://doi.org/10.3949/ccjm.87a.ccc024

    Prophylaxis against venous thromboembolism is recommended for all patients hospitalized with COVID-19.

  • Thoracic imaging in COVID-19
    Thoracic imaging in COVID-19
    Ruchi Yadav, MD, Debasis Sahoo, MD, FCCP and Ruffin Graham, MD
    Cleveland Clinic Journal of Medicine August 2020, 87 (8) 469-476; DOI: https://doi.org/10.3949/ccjm.87a.ccc032

    Typical findings include bilateral multifocal parenchymal opacities, predominantly in the peripheral and lower zones.

  • Cytokines and the still-baffling clinical biology of COVID-19
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine July 2020, 87 (7) 381-382; DOI: https://doi.org/10.3949/ccjm.87b.07020

    The primary culprit is not certain. Is it all immune damage, or is the continued persistence of coronavirus playing a role?

Pages